Clinical trials: Transplants
Gram-Negative Bacterial Infections, Gram-negative Bacteremia
Comparison of Solid Organ Transplant
Solid organ transplant (SOT) recipients have increased incidence of infections with MDRO pathogens. This difference leads to a disparity in antibiograms between SOT recipients and other hospitalized patients.
- Conditions
- Gram-Negative Bacterial Infections, Gram-negative Bacteremia, Multidrug-Resistant Organism, Hospital-acquired Pneumonia
- Trial name
- NCT04055922
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Methodist Health System
Leukemia
Autologous Stem Cell Transplants for Chronic Myelogenous Leukemia
Primary Objective: 1. To study ex-vivo purging of autologous hematopoietic stem cells that will be used to support high-dose chemotherapy in patients with chronic myelogenous leukemia (CML).
- Trial name
- NCT00446173
- Testing
- Busulfan, Cyclophosphamide, G-CSF
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
End Stage Renal Disease, Hepatitis C
Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time.
- Trial name
- NCT04575896
- Testing
- Glecaprevir/pibrentasvir
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Johns Hopkins University
Influenza Vaccine
Intradermal Versus Intramuscular Trivalent Influenza Vaccine in Adult Solid Organ Transplant Recipients
Influenza virus is an important cause of morbidity in the transplant population and can lead to viral and bacterial pneumonia and contribute to the development of rejection.
- Trial name
- NCT01180699
- Testing
- Influenza vaccine: Vaxigrip or Fluviral and Intanza
- Where
- Canada
- Volunteers
- 229 people
- Sponsor
- University of Alberta
Solid Organ Transplant Recipients, Skin Cancer
Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)
01.21 SiroSkin is a phase 3, double-blind, multi-centre, parallel-arm, randomised, placebo-controlled trial to evaluate the use of topical 1% sirolimus in the chemoprevention of skin cancer, versus placebo, applied every night…
- Trial name
- SiroSkin (NCT05860881)
- Testing
- Sirolimus Topical Cream
- Where
- 6 sites in Australia
- Volunteers
- 146 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Renal Transplantation
Study Evaluating Rapamune in Patients After Kidney Transplantation
The purpose of this study is to obtain data on the effectiveness and safety of Rapamune under everyday conditions
- Trial name
- NCT00240214
- Testing
- sirolimus
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
COVID-19, Organ Transplant
Transplantation of Deceased Donors With COVID-19 Into COVID-19 Negative Recipients Utilizing Casirivimab and Imdevimab Antibody Cocktail
This study will look to increase the donor pool for the solid organ transplant population by transplanting patients who died with COVID-19 but not from COVID-19 utilizing casirivimab and imdevimab antibody cocktail to prevent the…
- Trial name
- NCT05157997
- Testing
- Casirivimab and Imdevimab Antibody Cocktail
- Where
- United States
- Sponsor
- Northwell Health
Amyotrophic Lateral Sclerosis
Compassionate Treatment : An Exploratory Clinical Trial to Assess Treatment of Amyotrophic Lateral Sclerosis
The purpose of the study is to determine the safety and possible effectiveness of Autologous Adipose-Tissue Derived Stem Cells treatment in a Amyotrophic Lateral Sclerosis(ALS) patient.
- Trial name
- NCT02383654
- Testing
- Autologous Adipose-Tissue Derived Stem Cells
- Where
- Taiwan
- Volunteers
- 1 people
- Sponsor
- China Medical University Hospital
Infection in Solid Organ Transplant Recipients
Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)
The purpose of this study is to determine the safety and long-term immunogenicity of the 13-Valent Pneumococcal Conjugate vaccine in children who are solid organ transplant recipients.
- Trial name
- NCT01527591
- Testing
- Pneumococcal Conjugate Vaccine 13 (PCV13)
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, Los Angeles
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
Hepatitis C
Hepatitis C Positive Donor Into Hepatitis C Negative Recipients
Despite many efforts to increase the size of the donor pool, there is a large and growing disparity between the number of donor kidneys and livers available for transplantation and the number of patients on the transplant waiting…
- Trial name
- NCT03702218
- Testing
- Direct Acting Antivirals
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Heart Transplant Rejection
The TOGETHER Project - Heart
The researchers are trying to develop a way to measure the risk of transplant rejection with a blood test.
- Trial name
- TOGETHER (NCT03833050)
- Where
- 3 sites in United States
- Volunteers
- 101 people
- Sponsor
- Mayo Clinic
Transplants
Creating a Patient-centered Report Card for Solid Organ Transplant Candidates
Choosing a transplant center that will accept a particular candidate can be difficult and challenging for patients with end-stage organ failure.
- Trial name
- NCT03610555
- Testing
- Intervention 1 - SRTR (age question 1st), Intervention 2 - SRTR (BMI question 1st), Intervention 3 - TCST (age question 1st)
- Where
- United States
- Volunteers
- 268 people, healthy volunteers welcome
- Sponsor
- Ajay Israni, MD
Solid Organ Transplant Rejection, Chronic Kidney Failure
Exercise Training and Kidney Transplantation
The goal of this clinical trial is to investigate the physiological and molecular effects of exercise training in transplant recipients. The main questions it aims to answer are: 1.
- Conditions
- Solid Organ Transplant Rejection, Chronic Kidney Failure, Quality of Life, Inflammation
- Trial name
- EXTRA (NCT06216015)
- Testing
- Exercise training, Continue exercising, Discontinue exercising
- Volunteers
- 345 people
- Sponsor
- Hugo de Luca Correa
Kidney Transplantation
Pilot Study on the Use of Sirolimus to Treat Chronic Allograft Nephropathy in Children After Kidney Transplant
The purpose of this study is to determine whether treatment with sirolimus, in combination with low-dose tacrolimus and prednisone, is effective for the treatment of chronic allograft nephropathy (progressive scarring) in…
- Trial name
- NCT00188955
- Testing
- sirolimus
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University of Manitoba
Cancer
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell…
- Trial name
- NCT00045292
- Testing
- acyclovir, acyclovir sodium, valacyclovir
- Where
- 6 sites in United States
- Sponsor
- Fred Hutchinson Cancer Center
COVID-19, SARS-CoV-2 Infection
Immune Response to Third Dose of COVID-19 Vaccine in Solid Organ Transplant
The Coronavirus Disease 2019 (COVID-19) pandemic has claimed over 5 million lives globally. Fortunately, a substantial and growing number of SARS-CoV-2 vaccines with very high efficacy have been developed, manufactured, and…
- Conditions
- COVID-19, SARS-CoV-2 Infection, Solid Organ Transplant, Vaccine Response Impaired
- Trial name
- NCT05124509
- Testing
- Three doses of SARS-CoV-2 BNT162b2 vaccine (observational), Two doses of CoronaVac and one dose of BNT162b2 SARS-CoV-2 vaccine (observational)
- Where
- Chile
- Volunteers
- 147 people
- Sponsor
- Pontificia Universidad Catolica de Chile
HBV, Kidney Transplantation
Viral Immunity in Solid Organ Transplant Recipients: Monitoring Of The Response To Hepatitis B Booster Vaccination
Solid Organ Transplantation (SOT) is made possible by the use of a lifelong immunosuppressive treatment. This treatment limits the response of the immune system, enabling long-term survival of the transplanted organ, but also…
- Conditions
- HBV, Kidney Transplantation, Liver Transplantation
- Trial name
- VITAMIN (NCT06307808)
- Testing
- Tacrolimus, Belatacept
- Where
- France
- Volunteers
- 66 people
- Sponsor
- University Hospital, Grenoble
Immunosuppression, Kidney Transplantation
The Differential Effects of 3 Different Immunosuppressive
The study is a laboratory investigation comparing the regulatory effects of different immunosuppressive therapies in an in vitro human MLR assay of selecting specific immunosuppressive therapy to promote a regulatory profile and…
- Trial name
- NCT00729248
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Cytomegalovirus Infections, Solid Organ Transplant
A Dose-Escalation Study Evaluating Safety and Tolerability of Viral-Specific T Cells Against CMV in Adult Solid Organ Transplant Recipients
This study measures the tolerability of viral-specific T cells against Cytomegalovirus (CMV) in adult solid organ transplant (SOT) recipients. Participants are expected to be on study for 52 +/- 3 weeks.
- Trial name
- NCT03950414
- Testing
- CMV specific T-cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Wisconsin, Madison